FOMX FOAMIX PHARMACEUTICALS LTD

Foamix Pharmaceuticals to Participate in the Cantor Fitzgerald Global Healthcare Conference

Foamix Pharmaceuticals to Participate in the Cantor Fitzgerald Global Healthcare Conference

REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update at the Cantor Fitzgerald Global Healthcare Conference, taking place October 1-3 at the InterContinental New York Barclay Hotel.

Cantor Fitzgerald Global Healthcare Conference 2018

Date: Tuesday, October 2
Time:12:15pm Eastern Time
Location:InterContinental New York Barclay Hotel
Webcast:

About Foamix

Foamix is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, innovative and differentiated topical drugs for dermatological therapy. Our leading clinical stage product candidates are FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne and FMX103, our novel minocycline foam for the treatment of rosacea. We continue to pursue research & development of our proprietary, innovative foam technologies for the treatment of various skin conditions. We currently have development and license agreements relating to our technology with various pharmaceutical companies including LEO Pharma A/S, as assignee to our license with Bayer HealthCare, and others.

Foamix uses its website () as a channel to distribute information about Foamix and its product candidates from time to time. Foamix may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Foamix’s website in addition to following its press releases, filings with the Securities & Exchange Commission (“SEC”), public conference calls, and webcasts.

Contact:                                                        

Ilan Hadar, CFO & Country Manager 

Foamix Pharmaceuticals Ltd. 

 

US Investor Relations

Michael Rice

LifeSci Advisors, LLC

646-597-6979



EN
26/09/2018

Underlying

FOMXFOAMIX PHARMACEUTICALS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FOAMIX PHARMACEUTICALS LTD

 PRESS RELEASE
Free
FOMX FOAMIX PHARMACE...

Foamix Pharmaceuticals to Present at the Cowen and Company’s 40th An...

Foamix Pharmaceuticals to Present at the Cowen and Company’s 40th Annual Health Care Conference REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update at the Cowen 40th Annual Health Care Conference, taking place March 2-4, 2020 in Boston, Massachusetts. Presentat...

February 25, 2020 1 EN
 PRESS RELEASE
Free
FOMX FOAMIX PHARMACE...

Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topi...

Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced results from an integrated efficacy analysis on the two pivotal Phase 3 clinical trials for FMX103 (minocycline, 1.5% foam) currently under review by the U.S. Food and D...

February 18, 2020 1 EN
 PRESS RELEASE
Free
FOMX FOAMIX PHARMACE...

Foamix and Menlo Announce Shareholder Approval of Proposed Merger

Foamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020 REHOVOT, Israel and BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder proposals necessary to complete the previously announced merger at their respective shareholder / stockholder meetings held earlier today. Pending the expiration of a 30...

February 6, 2020 1 EN
 PRESS RELEASE
Free
FOMX FOAMIX PHARMACE...

Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for ...

Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today the publication of the Company’s Phase 3 studies FX2016-11 and FX2016-12 (Studies 11 & 12) in the (JAAD).  Studies 11 and 12 were conducted by Foamix to support the New Drug Application (NDA) submission of FMX103 (minocycline, 1.5% foam...

February 6, 2020 1 EN
 PRESS RELEASE
Free
FOMX FOAMIX PHARMACE...

Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics

Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics REHOVOT, Israel, and BRIDGEWATER, N.J., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a significant shareholder of the Company, intends to vote in favor of the proposed merger with Menlo Therapeutics at the Company’s upcoming extraordinary general meeting of shareholders. OrbiMed expressed its support for the transaction in a issued on January 16, 2020. Perceptive Advisor...

January 17, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch